CoChat

In vitro structure–activity relationships and forensic case series of emerging 2-benzylbenzimidazole ‘nitazene’ opioids

Open access

The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.

Abstract

2-Benzylbenzimidazole ‘nitazene’ opioids are presenting a growing threat to public health. Although various nitazenes were previously studied, systematic comparisons of the effects of different structural modifications to the 2-benzylbenzimidazole core structure on μ-opioid receptor (MOR) activity are limited. Here, we assessed in vitro structure–activity relationships of 9 previously uncharacterized nitazenes alongside known structural analogues. Specifically, we focused on MOR activation by ‘ring’ substituted analogues (i.e., N -pyrrolidino and N -piperidinyl modifications), ‘desnitazene’ analogues (lacking the 5-nitro group), and N -desethyl analogues. The results from two in vitro MOR activation assays (β-arrestin 2 recruitment and inhibition of cAMP accumulation) showed that ‘ring’ modifications overall yield highly active drugs. With the exception of 4′-OH analogues (which are metabolites), N -pyrrolidino substitutions were generally more favorable for MOR activation than N -piperidine substitutions. Furthermore, removal of the 5-nitro group on the benzimidazole ring consistently caused a pronounced decrease in potency. The N -desethyl modifications showed important MOR activity, and generally resulted in a slightly lowered potency than comparator nitazenes. Intriguingly, N -desethyl isotonitazene was the exception and was consistently more potent than isotonitazene. Complementing the in vitro findings and demonstrating the high harm potential associated with many of these compounds, we describe 85 forensic cases from North America and the United Kingdom involving etodesnitazene, N -desethyl etonitazene, N -desethyl isotonitazene, N -pyrrolidino metonitazene, and N -pyrrolidino protonitazene. The low-to-sub ng/mL blood concentrations observed in most cases underscore the drugs’ high potencies. Taken together, by bridging pharmacology and case data, this study may aid to increase awareness and guide legislative and public health efforts.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s00204-024-03774-7

Cites

53 of 53 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Structure of isotonitazene (left) and generic structure of 2-benzylbenzimidazole ‘nitazene’ opioids (right). The highlighted R groups correspond to the substitutions as indicated in Table 1 (color figure online)
Fig. 1 Structure of isotonitazene (left) and generic structure of 2-benzylbenzimidazole ‘nitazene’ opioids (right). The highlighted R groups correspond to the substitutions as indicated in Table 1 (color figure online)CC BY · PubMed Central
Fig. 2 Timeline of the appearance of nitazenes on the recreational drug market in the United States (U.S.). With the exception of etonitazene (which was reported in the U.S. in 2003 but not since Reavy 2003; Morris 2009)) and 5-methyl etodesnitazene (Krotulski et al. 2024), dates indicate the date of receipt of forensic case samples and/or drug materials at the Center for Forensic Science Research and Education (CFSRE) (color figure online)
Fig. 2 Timeline of the appearance of nitazenes on the recreational drug market in the United States (U.S.). With the exception of etonitazene (which was reported in the U.S. in 2003 but not since Reavy 2003; Morris 2009)) and 5-methyl etodesnitazene (Krotulski et al. 2024), dates indicate the date of receipt of forensic case samples and/or drug materials at the Center for Forensic Science Research and Education (CFSRE) (color figure online)CC BY · PubMed Central
Fig. 3 μ-Opioid receptor (MOR) activation profiles (MOR-βarr2 and GloSensor® cAMP assays) for analogues of metonitazene (A), etonitazene (B), protonitazene (C), isotonitazene (D), and 4′-OH nitazene (E). Comparator drugs and reference nitazenes are shown in F. Data are presented as mean receptor activation ± standard error of the mean (SEM) (n ≥ 3) and are normalized to the Emax of hydromorphone (HM) (= 100%). The dotted line represents the maximum MOR activation produced by DAMGO. AUC, area under the curve. Note the differences in scales of the axes (color figure online)
Fig. 3 μ-Opioid receptor (MOR) activation profiles (MOR-βarr2 and GloSensor® cAMP assays) for analogues of metonitazene (A), etonitazene (B), protonitazene (C), isotonitazene (D), and 4′-OH nitazene (E). Comparator drugs and reference nitazenes are shown in F. Data are presented as mean receptor activation ± standard error of the mean (SEM) (n ≥ 3) and are normalized to the Emax of hydromorphone (HM) (= 100%). The dotted line represents the maximum MOR activation produced by DAMGO. AUC, area under the curve. Note the differences in scales of the axes (color figure online)CC BY · PubMed Central
Fig. 4 Comparison of obtained efficacies (Emax, relative to hydromorphone (HM)) (A) and potencies (pEC50) (B) of the evaluated compounds (1–25, A–D) in the MOR-βarr2 and the GloSensor® cAMP assays (color figure online)
Fig. 4 Comparison of obtained efficacies (Emax, relative to hydromorphone (HM)) (A) and potencies (pEC50) (B) of the evaluated compounds (1–25, A–D) in the MOR-βarr2 and the GloSensor® cAMP assays (color figure online)CC BY · PubMed Central
Fig. 5 Prevalence of etodesnitazene (yellow squares), N-pyrrolidino protonitazene (green crosses), N-pyrrolidino metonitazene (blue circles), N-desethyl isotonitazene (red triangles), and N-desethyl etonitazene (purple diamond) between Q2 2020 and Q3 2023 in North America, according to the results of comprehensive toxicological testing by the CFSRE, at the time of data compilation (Q1 2024). Unless noted in Table S6-1/2/3, dates represent the date of sample collection. Etodesnitazene emerged in Q2 2020 and reached peak prevalence in 2021. N-Pyrrolidino protonitazene, N-pyrrolidino metonitazene, and N-desethyl isotonitazene all emerged in Q4 2022, while N-desethyl etonitazene emerged in Q3 2023. The 11 reported cases from the U.K. (5 involving N-pyrrolidino protonitazene, from Q2 to Q3 2023, 5 involving N-desethyl isotonitazene, from Q3 to Q4 2023, and 1 involving both N-pyrrolidino protonitazene and N-pyrrolidino metonitazene, from Q3 2023) are not included in the figure. Note that some cases were positive for more than one of the listed nitazenes (color figure online)
Fig. 5 Prevalence of etodesnitazene (yellow squares), N-pyrrolidino protonitazene (green crosses), N-pyrrolidino metonitazene (blue circles), N-desethyl isotonitazene (red triangles), and N-desethyl etonitazene (purple diamond) between Q2 2020 and Q3 2023 in North America, according to the results of comprehensive toxicological testing by the CFSRE, at the time of data compilation (Q1 2024). Unless noted in Table S6-1/2/3, dates represent the date of sample collection. Etodesnitazene emerged in Q2 2020 and reached peak prevalence in 2021. N-Pyrrolidino protonitazene, N-pyrrolidino metonitazene, and N-desethyl isotonitazene all emerged in Q4 2022, while N-desethyl etonitazene emerged in Q3 2023. The 11 reported cases from the U.K. (5 involving N-pyrrolidino protonitazene, from Q2 to Q3 2023, 5 involving N-desethyl isotonitazene, from Q3 to Q4 2023, and 1 involving both N-pyrrolidino protonitazene and N-pyrrolidino metonitazene, from Q3 2023) are not included in the figure. Note that some cases were positive for more than one of the listed nitazenes (color figure online)CC BY · PubMed Central
Fig. 6 Geographical distribution of etodesnitazene, N-pyrrolidino protonitazene, N-pyrrolidino metonitazene, N-desethyl etonitazene, and N-desethyl isotonitazene cases in the U.S. (9 cases for etodesnitazene and 1 case for N-pyrrolidino protonitazene from Vancouver, Canada, are also included in the bar chart in B). The U.S. maps shown in A were created with mapchart.net (color figure online)
Fig. 6 Geographical distribution of etodesnitazene, N-pyrrolidino protonitazene, N-pyrrolidino metonitazene, N-desethyl etonitazene, and N-desethyl isotonitazene cases in the U.S. (9 cases for etodesnitazene and 1 case for N-pyrrolidino protonitazene from Vancouver, Canada, are also included in the bar chart in B). The U.S. maps shown in A were created with mapchart.net (color figure online)CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

7 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 7

  1. Brandenberger H (1974) Rolle des massenspektrometers im toxikologisch-chemischen laboratorium. Dtsch Lebensm-Rundsch 70:31–39
  2. EMCDDA (2020) Report on the risk assessment of N,N-diethyl-2-[[4-(1-methylethoxy) phenyl] methyl]-5-nitro-1H-benzimidazole-1-ethanamine (isotonitazene) in accordance with Article 5c of Regulation (EC) No 1920/2006 (as amended). Publications Office, Luxembourg
  3. EMCDDA (2023) European drug report 2023: trends and developments. Publications Office of the European Union, Luxembourg
  4. Krotulski A, Papsun D, Walton SE, Logan BK (2022) Benzo-dope: an increasingly prevalent drug combination of significant toxicological relevance. Society of forensic toxicologist (SOFT)- 2022 conference meeting
  5. Sorokin VI (1999) Illegal synthesis of etonitazene. J Clan Lab Invest Chem Assoc 9:20
  6. Sorokin VI, Ponkratov KV, Drozdov MA (1999) Etonitazene encountered in Moscow. Microgram 32:239
  7. UNODC (2020) The growing complexity of the opioid crisis. Global SMART update (2020) vol 24. Austria, Vienna

Cited by

See all 62

Metadata

Authors
De Vrieze, L. M., Walton, S. E., Pottie, E., Papsun, D., Logan, B. K., Krotulski, A. J., Stove, C. P., & Vandeputte, M. M.
Affiliations
  • Fredric Rieders Family Foundation (US)
  • Ghent University (BE)
Corresponding author
  • Stove, Christophe P.
  • Vandeputte, Marthe M.
Venue
Archives of Toxicology
Published
2024-06-14
Volume
98
Issue
9
Pages
2999-3018
ISSN
  • 0340-5761 (ISSN-L)
  • 1432-0738
OpenAlex
W4399665315
Cited by
58
References
53
Citations by year
2026: 22 · 2025: 31 · 2024: 5
FWCI
13.73
Type
journal article
Language
en
Open access
Licence
Locations
  • Archives of Toxicology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Ghent University Academic Bibliography (Ghent University) (submittedVersion, cc-by)
Funders
  • Office of Justice Programs (15PNIJ-22-GG-04434-MUMU)
  • Fonds Wetenschappelijk Onderzoek (11I5623N, 1S81522N, G069419N)
  • Bijzonder Onderzoeksfonds UGent (BOF23/PDO/073, 01J15517)
Topics
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Forensic Toxicology and Drug Analysis
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Alkaloids: synthesis and pharmacology
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
Keywords
structure-activity relationship, mu-opioid receptor, etonitazene, isotonitazene, opioid potency, forensic toxicology
MeSH terms
Analgesics, Opioid, Animals, Benzimidazoles, Humans, Nitro Compounds, Structure-Activity Relationship, Receptors, Opioid, mu, HEK293 Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.